Cellumed Statistics
Total Valuation
Cellumed has a market cap or net worth of KRW 38.46 billion. The enterprise value is 45.34 billion.
| Market Cap | 38.46B |
| Enterprise Value | 45.34B |
Important Dates
The last earnings date was Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellumed has 54.95 million shares outstanding. The number of shares has increased by 16.33% in one year.
| Current Share Class | 54.95M |
| Shares Outstanding | 54.95M |
| Shares Change (YoY) | +16.33% |
| Shares Change (QoQ) | +5.78% |
| Owned by Insiders (%) | 0.55% |
| Owned by Institutions (%) | 2.29% |
| Float | 42.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.27 |
| PB Ratio | 4.54 |
| P/TBV Ratio | 4.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.45 |
| EV / Sales | 0.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.31 |
Financial Position
The company has a current ratio of 0.92, with a Debt / Equity ratio of 1.59.
| Current Ratio | 0.92 |
| Quick Ratio | 0.40 |
| Debt / Equity | 1.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.57 |
| Interest Coverage | -13.33 |
Financial Efficiency
Return on equity (ROE) is -159.78% and return on invested capital (ROIC) is -24.49%.
| Return on Equity (ROE) | -159.78% |
| Return on Assets (ROA) | -9.93% |
| Return on Invested Capital (ROIC) | -24.49% |
| Return on Capital Employed (ROCE) | -113.80% |
| Revenue Per Employee | 1.61B |
| Profits Per Employee | -346.75M |
| Employee Count | 90 |
| Asset Turnover | 1.88 |
| Inventory Turnover | 20.62 |
Taxes
| Income Tax | -241.71M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.99% in the last 52 weeks. The beta is 1.23, so Cellumed's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | -67.99% |
| 50-Day Moving Average | 720.60 |
| 200-Day Moving Average | 1,039.12 |
| Relative Strength Index (RSI) | 47.63 |
| Average Volume (20 Days) | 2,173,133 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cellumed had revenue of KRW 144.54 billion and -31.21 billion in losses. Loss per share was -599.72.
| Revenue | 144.54B |
| Gross Profit | 4.04B |
| Operating Income | -12.21B |
| Pretax Income | -31.61B |
| Net Income | -31.21B |
| EBITDA | -11.28B |
| EBIT | -12.21B |
| Loss Per Share | -599.72 |
Balance Sheet
The company has 6.73 billion in cash and 13.43 billion in debt, giving a net cash position of -6.70 billion or -122.00 per share.
| Cash & Cash Equivalents | 6.73B |
| Total Debt | 13.43B |
| Net Cash | -6.70B |
| Net Cash Per Share | -122.00 |
| Equity (Book Value) | 8.47B |
| Book Value Per Share | 150.91 |
| Working Capital | -5.39B |
Cash Flow
In the last 12 months, operating cash flow was -7.27 billion and capital expenditures -1.27 billion, giving a free cash flow of -8.53 billion.
| Operating Cash Flow | -7.27B |
| Capital Expenditures | -1.27B |
| Free Cash Flow | -8.53B |
| FCF Per Share | -155.33 |
Margins
Gross margin is 2.80%, with operating and profit margins of -8.45% and -21.59%.
| Gross Margin | 2.80% |
| Operating Margin | -8.45% |
| Pretax Margin | -21.87% |
| Profit Margin | -21.59% |
| EBITDA Margin | -7.81% |
| EBIT Margin | -8.45% |
| FCF Margin | n/a |
Dividends & Yields
Cellumed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.33% |
| Shareholder Yield | -16.33% |
| Earnings Yield | -81.14% |
| FCF Yield | -22.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 28, 2017. It was a reverse split with a ratio of 0.1.
| Last Split Date | Apr 28, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Cellumed has an Altman Z-Score of -0.54 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.54 |
| Piotroski F-Score | 2 |